Stocktoria
Cardiff Oncology, Inc. CRDF
Cardiff Oncology, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $593,000 | $683,000 | $488,000 | $386,000 | $359,000 | $366,000 | $244,632 | $378,325 | $505,404 | $381,072 |
| R&D expense | — | — | — | $27.1M | $17.4M | $11.2M | — | — | — | — |
| SG&A expense | $14.2M | $12.5M | $13.0M | $13.2M | $11.8M | $8.2M | $5.8M | $8.0M | $14.2M | — |
| Operating income | -$49.0M | -$48.7M | -$45.4M | -$39.9M | -$28.9M | -$19.1M | -$16.7M | -$17.1M | -$25.6M | -$40.1M |
| Interest expense | — | — | — | — | $0 | $2,000 | $0 | $25,409 | $1.0M | $1.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$45.9M | -$45.4M | -$41.4M | -$38.7M | -$28.3M | -$19.3M | -$16.4M | -$16.5M | -$24.9M | -$39.2M |
| EPS (diluted) | $-0.69 | $-0.95 | $-0.93 | $-0.89 | $-0.73 | $-1.08 | — | $-8.26 | $-51.76 | $-1.37 |
| Operating cash flow | -$37.9M | -$37.7M | -$30.9M | -$33.8M | -$23.0M | -$16.3M | -$13.3M | -$13.2M | -$23.3M | -$31.0M |
| Free cash flow | -$38.0M | -$37.8M | -$31.5M | -$34.8M | -$23.2M | -$16.5M | -$13.3M | -$13.2M | -$23.4M | -$31.9M |
| Cash & equivalents | $17.5M | $51.5M | $21.7M | $16.3M | $11.9M | $131.0M | $10.2M | $11.5M | $8.2M | $13.9M |
| Total assets | $61.9M | $97.2M | $81.6M | $116.2M | $149.5M | $134.7M | $13.1M | $14.2M | $12.3M | $44.0M |
| Total liabilities | $16.5M | $14.2M | $11.9M | $9.8M | $9.1M | $6.6M | $5.8M | $4.1M | $5.8M | $24.2M |
| Shareholders' equity | $45.4M | $82.9M | $69.7M | $106.3M | $140.4M | $128.2M | $7.3M | $10.1M | $6.5M | $19.8M |
Growth · year-over-year · Revenue CAGR 5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -13.2% | +40.0% | +26.4% | +7.5% | -1.9% | +49.6% | -35.3% | -25.1% | +32.6% | +21.8% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.